Ototoxicity of tobramycin: a clinical overview.
In a survey of data on 3,506 patients treated with tobramycin, the 21 cases of drug-related ototoxicity are reported and reviewed. In seven patients the effects were auditory only, in nine vestibular only, and in five both auditory and vestibular. Effects subsided in 14 of the 18 patients who were available for monitoring after therapy. High-frequency audiometric losses persisted in three patients, and a hearing decrease persisted in one. In only one of the three patients did audiometric losses exceed 40 decibels. The patients with drug-related ototoxicity were compared to a group of 49 patients for whom both audiometric testing (before and after therapy) and clinical observation showed that no ototoxic reactions had occurred. Preexisting renal impairment, prior and/or concomitant therapy with other possibly ototoxic drugs, and therapy for 10 days or more with a dose of greater than 3 mg/kg per day were found to be associated with ototoxicity.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001299:Audiometry; D004423:Ear / Q000187:drug effects*; D005260:Female; D006309:Hearing / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk; D014012:Tinnitus / Q000139:chemically induced; D014031:Tobramycin / Q000009:adverse effects*; D014722:Vestibule, Labyrinth / Q000187:drug effects
D000900:Anti-Bacterial Agents; D014031:Tobramycin